SCHEMBL5999962

SCHEMBL5999962

CCC(N)(c1ccncc1)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.39
ROCK1 Q13464 1/20 0.33
MAPT P10636 2/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
CYP3A4 P08684 2/20 0.31
CYP2D6 P10635 2/20 0.31
KDM4E B2RXH2 2/20 0.31
CYP1A2 P05177 2/20 0.31
CYP2C9 P11712 2/20 0.31
CYP2C19 P33261 2/20 0.31
CRHR1 P34998 1/20 0.31
PSEN1 P49768 1/20 0.30
PSEN2 P49810 1/20 0.30
APH1B Q8WW43 1/20 0.30
NCSTN Q92542 1/20 0.30
APH1A Q96BI3 1/20 0.30
PSENEN Q9NZ42 1/20 0.30
KIF11 P52732 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5999689 0.85 CYP19A1 (0.55) CYP19A1KMT2AMEN1
SCHEMBL6000276 0.85 CYP19A1 (0.43) CYP19A1ROCK1MAPTKMT2AMEN1
SCHEMBL5999986 0.82 CYP19A1 (0.48) CYP19A1CYP3A4
SCHEMBL5999593 0.79 TSHR (0.41) CYP19A1MAPTKMT2AMEN1CYP3A4
SCHEMBL5999958 0.79 RAB9A (0.39) KIF11
SCHEMBL5999634 0.78 CYP19A1 (0.41) CYP19A1ROCK1MAPTKMT2AMEN1
SCHEMBL5999709 0.77 KIF11 (0.49) MAPTKIF11ALDH1A1
SCHEMBL6000325 0.76 CYP17A1 (0.39) CYP19A1CYP3A4CYP1A2KIF11
SCHEMBL5999948 0.76 TSHR (0.38) CYP19A1KMT2ACYP3A4KDM4EKIF11
SCHEMBL5999951 0.74 USP2 (0.55) CYP19A1KDM4EKIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCE, INC. (US) 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C CYP19A1 4624/4885ROCK1 3557/4885MAPT 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.